Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$4.23
-0.17-3.86%
At close: -
$4.30
0.071.65%
After Hours: May 9, 5:31 PM EDT
Comments
Loading...
Astria Therapeutics Analyst Ratings and Price Targets | NASDAQ:ATXS | Benzinga
Astria Therapeutics Inc has a consensus price target of $27.89 based on the ratings of 9 analysts. The high is $47 issued by Cantor Fitzgerald on April 29, 2025. The low is $16 issued by HC Wainwright & Co. on March 11, 2025. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Wedbush, and HC Wainwright & Co. on April 29, 2025, March 12, 2025, and March 11, 2025, respectively. With an average price target of $30.33 between Cantor Fitzgerald, Wedbush, and HC Wainwright & Co., there's an implied 605.43% upside for Astria Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Wedbush
HC Wainwright & Co.
Citizens Capital Markets
JMP Securities
1calculated from analyst ratings
Analyst Ratings for Astria Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/29/2025 | Buy Now | 993.02% | Cantor Fitzgerald | Steven Seedhouse58% | → $47 | Initiates | → Overweight | Get Alert |
| 03/12/2025 | Buy Now | 551.16% | Wedbush | Laura Chico47% | $27 → $28 | Maintains | Outperform | Get Alert |
| 03/11/2025 | Buy Now | 272.09% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 03/03/2025 | Buy Now | 504.65% | Citizens Capital Markets | Jonathan Wolleben69% | $26 → $26 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/27/2025 | Buy Now | 272.09% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 01/31/2025 | Buy Now | 504.65% | JMP Securities | Jonathan Wolleben69% | → $26 | Initiates | → Market Outperform | Get Alert |
| 01/23/2025 | Buy Now | 272.09% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 01/13/2025 | Buy Now | 272.09% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 12/11/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis44% | — | Reiterates | Buy → Buy | Get Alert |
| 12/10/2024 | Buy Now | 272.09% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 272.09% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 551.16% | Oppenheimer | Hartaj Singh45% | $26 → $28 | Maintains | Outperform | Get Alert |
| 09/27/2024 | Buy Now | 272.09% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 411.63% | Wedbush | Laura Chico47% | $22 → $22 | Reiterates | Outperform → Outperform | Get Alert |
| 08/13/2024 | Buy Now | 504.65% | Oppenheimer | Hartaj Singh45% | $25 → $26 | Maintains | Outperform | Get Alert |
| 08/13/2024 | Buy Now | 272.09% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 07/29/2024 | Buy Now | 713.95% | TD Cowen | Stacy Ku20% | → $35 | Initiates | → Buy | Get Alert |
| 05/21/2024 | Buy Now | 481.4% | Oppenheimer | Hartaj Singh45% | $29 → $25 | Maintains | Outperform | Get Alert |
| 05/10/2024 | Buy Now | 272.09% | HC Wainwright & Co. | Joseph Pantginis44% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | 411.63% | Wedbush | Laura Chico47% | $22 → $22 | Reiterates | Outperform → Outperform | Get Alert |
| 04/23/2024 | Buy Now | 272.09% | HC Wainwright & Co. | Joseph Pantginis44% | $18 → $16 | Maintains | Buy | Get Alert |
| 03/26/2024 | Buy Now | 574.42% | Oppenheimer | Hartaj Singh45% | $25 → $29 | Maintains | Outperform | Get Alert |
| 03/26/2024 | Buy Now | 411.63% | Wedbush | Laura Chico47% | $17 → $22 | Maintains | Outperform | Get Alert |
| 03/25/2024 | Buy Now | 527.91% | Jefferies | Eun Yang33% | $22 → $27 | Maintains | Buy | Get Alert |
| 03/25/2024 | Buy Now | 318.6% | HC Wainwright & Co. | Joseph Pantginis44% | $18 → $18 | Maintains | Buy | Get Alert |
| 03/14/2024 | Buy Now | 318.6% | HC Wainwright & Co. | Joseph Pantginis44% | → $18 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2024 | Buy Now | 318.6% | HC Wainwright & Co. | Joseph Pantginis44% | $18 → $18 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2024 | Buy Now | 295.35% | Wedbush | Laura Chico47% | $17 → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 01/30/2024 | Buy Now | 295.35% | Wedbush | Laura Chico47% | $17 → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 11/15/2023 | Buy Now | 481.4% | Oppenheimer | Hartaj Singh45% | $30 → $25 | Maintains | Outperform | Get Alert |
| 10/13/2023 | Buy Now | 318.6% | Wedbush | Laura Chico47% | $25 → $18 | Maintains | Outperform | Get Alert |
| 10/12/2023 | Buy Now | 318.6% | HC Wainwright & Co. | Joseph Pantginis44% | $20 → $18 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 481.4% | Wedbush | Laura Chico47% | $26 → $25 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | 365.12% | HC Wainwright & Co. | Joseph Pantginis44% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 06/08/2023 | Buy Now | 597.67% | Oppenheimer | Hartaj Singh45% | → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 05/12/2023 | Buy Now | 504.65% | Wedbush | Laura Chico47% | → $26 | Reiterates | → Outperform | Get Alert |
| 05/12/2023 | Buy Now | 365.12% | HC Wainwright & Co. | Joseph Pantginis44% | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2023 | Buy Now | 318.6% | Evercore ISI Group | Liisa Bayko70% | → $18 | Initiates | → Outperform | Get Alert |
| 02/24/2023 | Buy Now | 365.12% | HC Wainwright & Co. | Joseph Pantginis44% | → $20 | Reiterates | → Buy | Get Alert |
| 12/19/2022 | Buy Now | 365.12% | HC Wainwright & Co. | Joseph Pantginis44% | $13 → $20 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Astria Therapeutics (ATXS) stock?
The latest price target for Astria Therapeutics (NASDAQ:ATXS) was reported by Cantor Fitzgerald on April 29, 2025. The analyst firm set a price target for $47.00 expecting ATXS to rise to within 12 months (a possible 993.02% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Astria Therapeutics (ATXS)?
The latest analyst rating for Astria Therapeutics (NASDAQ:ATXS) was provided by Cantor Fitzgerald, and Astria Therapeutics initiated their overweight rating.
When was the last upgrade for Astria Therapeutics (ATXS)?
There is no last upgrade for Astria Therapeutics
When was the last downgrade for Astria Therapeutics (ATXS)?
There is no last downgrade for Astria Therapeutics.
When is the next analyst rating going to be posted or updated for Astria Therapeutics (ATXS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Astria Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Astria Therapeutics was filed on April 29, 2025 so you should expect the next rating to be made available sometime around April 29, 2026.
Is the Analyst Rating Astria Therapeutics (ATXS) correct?
While ratings are subjective and will change, the latest Astria Therapeutics (ATXS) rating was a initiated with a price target of $0.00 to $47.00. The current price Astria Therapeutics (ATXS) is trading at is $4.30, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
